GENSIGHT BIOLOGICS SA (SIGHT.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:SIGHT - FR0013183985 - Common Stock
SIGHT.PA Key Statistics, Chart & Performance
The current stock price of SIGHT.PA is 0.1 EUR. In the past month the price decreased by -18.85%. In the past year, price decreased by -67.75%.
SIGHT.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 72.65 | 47.68B | ||
| 1AE.DE | ARGENX SE | 73.4 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.86B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.80B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.91B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.80B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.79B | ||
| 5CV.DE | CUREVAC NV | 7.64 | 997.95M | ||
| NANO.PA | NANOBIOTIX | N/A | 872.70M | ||
| 6IV.DE | INVENTIVA SA | N/A | 678.11M | ||
| PHIL.MI | PHILOGEN SPA | 20.35 | 678.37M | ||
| IVA.PA | INVENTIVA SA | N/A | 687.66M |
Related stock screener links
About SIGHT.PA
Company Profile
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. The company is headquartered in Paris, Ile-De-France and currently employs 13 full-time employees. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Company Info
GENSIGHT BIOLOGICS SA
74 Rue du Faubourg Saint-Antoine
Paris ILE-DE-FRANCE FR
Employees: 16
Phone: 33176217220
GENSIGHT BIOLOGICS SA / SIGHT.PA FAQ
What does SIGHT do?
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. The company is headquartered in Paris, Ile-De-France and currently employs 13 full-time employees. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
What is the current price of SIGHT stock?
The current stock price of SIGHT.PA is 0.1 EUR. The price decreased by -1.57% in the last trading session.
Does GENSIGHT BIOLOGICS SA pay dividends?
SIGHT.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of SIGHT stock?
SIGHT.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in GENSIGHT BIOLOGICS SA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SIGHT.PA.
Can you provide the number of employees for GENSIGHT BIOLOGICS SA?
GENSIGHT BIOLOGICS SA (SIGHT.PA) currently has 16 employees.
What is GENSIGHT BIOLOGICS SA worth?
GENSIGHT BIOLOGICS SA (SIGHT.PA) has a market capitalization of 19.05M EUR. This makes SIGHT.PA a Nano Cap stock.
SIGHT.PA Technical Analysis
SIGHT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SIGHT.PA. Both the profitability and financial health of SIGHT.PA have multiple concerns.
SIGHT.PA Financial Highlights
Over the last trailing twelve months SIGHT.PA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 78.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -205.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SIGHT.PA Forecast & Estimates
11 analysts have analysed SIGHT.PA and the average price target is 0.44 EUR. This implies a price increase of 338.6% is expected in the next year compared to the current price of 0.1.
For the next year, analysts expect an EPS growth of 35.4% and a revenue growth 29.37% for SIGHT.PA